Cargando…
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620836/ https://www.ncbi.nlm.nih.gov/pubmed/36325433 http://dx.doi.org/10.2147/NDT.S392309 |
| _version_ | 1784821404137422848 |
|---|---|
| author | da Silva, Vinicius Trindade Gomes Gebrin, Thiago Paiva, Wellingson Silva |
| author_facet | da Silva, Vinicius Trindade Gomes Gebrin, Thiago Paiva, Wellingson Silva |
| author_sort | da Silva, Vinicius Trindade Gomes |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9620836 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96208362022-11-01 Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] da Silva, Vinicius Trindade Gomes Gebrin, Thiago Paiva, Wellingson Silva Neuropsychiatr Dis Treat Letter Dove 2022-10-27 /pmc/articles/PMC9620836/ /pubmed/36325433 http://dx.doi.org/10.2147/NDT.S392309 Text en © 2022 da Silva et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Letter da Silva, Vinicius Trindade Gomes Gebrin, Thiago Paiva, Wellingson Silva Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title | Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title_full | Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title_fullStr | Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title_full_unstemmed | Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title_short | Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter] |
| title_sort | bevacizumab for the treatment of high-grade meningiomas: is there new evidence? [letter] |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620836/ https://www.ncbi.nlm.nih.gov/pubmed/36325433 http://dx.doi.org/10.2147/NDT.S392309 |
| work_keys_str_mv | AT dasilvaviniciustrindadegomes bevacizumabforthetreatmentofhighgrademeningiomasistherenewevidenceletter AT gebrinthiago bevacizumabforthetreatmentofhighgrademeningiomasistherenewevidenceletter AT paivawellingsonsilva bevacizumabforthetreatmentofhighgrademeningiomasistherenewevidenceletter |